Global Pharmaceuticals & Biotech High Insider Buying

Nuo Therapeutics

Market Cap: US$85.9m

Operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States.

ME Therapeutics Holdings

Market Cap: CA$118.4m

A preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology.

ALX Oncology Holdings

Market Cap: US$83.0m

A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.

Vaxart

Market Cap: US$82.2m

A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States.

Recce Pharmaceuticals

Market Cap: AU$120.0m

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States.

CEL-SCI

Market Cap: US$71.8m

A clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.

Medexus Pharmaceuticals

Market Cap: CA$96.6m

Operates as a pharmaceutical company in Canada and the United States.

Immix Biopharma

Market Cap: US$67.0m

A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.

Quantum BioPharma

Market Cap: CA$92.3m

Operates as a biopharmaceutical company.

Vext Science

Market Cap: CA$86.1m

Through its subsidiaries, provides integrated agricultural technology, services, and property management services in the cannabis industry in the United States.

Enzymatica

Market Cap: SEK 577.7m

A life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract.

Precision BioSciences

Market Cap: US$60.5m

A clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.

Camp4 Therapeutics

Market Cap: US$56.2m

A clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases.

MTL Cannabis

Market Cap: CA$78.2m

Through its subsidiaries, engages in the cultivation and production of cannabis products for recreational and medical purposes in Canada.

Relmada Therapeutics

Market Cap: US$54.8m

Operates as a clinical-stage biotechnology company in the United States.

Amplia Therapeutics

Market Cap: AU$82.1m

A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.

Vitrafy Life Sciences

Market Cap: AU$79.8m

Engages in the research, development, and commercialization of cryopreservation solutions in Australia.

Earth Science Tech

Market Cap: US$51.2m

Together with its subsidies, focuses on health and wellness industry.

FibroGen

Market Cap: US$50.1m

A biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.

Jupiter Neurosciences

Market Cap: US$48.8m

A clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation.

Sona Nanotech

Market Cap: CA$67.7m

Operates as a nanotechnology life sciences company.

CalciMedica

Market Cap: US$43.7m

A clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.

RenovoRx

Market Cap: US$42.9m

A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.

Ascelia Pharma

Market Cap: SEK 400.3m

A biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden.

Dyadic International

Market Cap: US$41.5m

A biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally.

Plus Therapeutics

Market Cap: US$40.1m

A clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.

Navamedic

Market Cap: NOK 383.3m

A pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally.

Jasper Therapeutics

Market Cap: US$37.9m

A clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.

Akari Therapeutics

Market Cap: US$36.2m

An oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins.

NeuroScientific Biopharmaceuticals

Market Cap: AU$54.9m

Engages in the research and development of novel peptide-based pharmaceutical products.

ZYUS Life Sciences

Market Cap: CA$49.2m

Manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union.

Mendus

Market Cap: SEK 332.3m

A biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors.

Iterum Therapeutics

Market Cap: US$34.8m

A pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States.

Promimic

Market Cap: SEK 313.6m

Manufactures, markets, and sells biomaterials for improved osseointegration for orthopedic and dental implants markets.

Harvard Apparatus Regenerative Technology

Market Cap: US$31.6m

A clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects.

Oncotelic Therapeutics

Market Cap: US$31.0m

A clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications.